Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels - PubMed (original) (raw)

. 2000 Dec;50(12):1063-70.

doi: 10.1055/s-0031-1300346.

Affiliations

• PMID: 11190770
• DOI: 10.1055/s-0031-1300346

Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels

C Rundfeldt et al. Arzneimittelforschung. 2000 Dec.

Abstract

Retigabine (N-(2-amino-4-(4-fluorobenzylamino)phenyl) carbamic acid ethyl ester, CAS 150812-12-7, D-23129) is a novel anticonvulsant currently undergoing phase II clinical trials. The compound was shown to possess broad spectrum and potent anticonvulsant properties both in vitro and in vivo. The mechanism of action of this drug is currently not fully understood. In previous studies a potent opening effect on K+ channels and an increased release of newly synthesized gamma-aminobutyric acid (GABA) were reported. The aim of this study was to investigate the interaction of retigabine with GABA, kainate and N-methyl-D-aspartate (NMDA) induced currents as well as with voltage gated Na+ and Ca++ channels. Retigabine concentration dependently potentiated GABA induced currents in rat cortical neurones. Significant effects were only seen with concentrations of 10 mumol/l and above. The action of retigabine was not antagonised by flumazenil indicating interaction with other than benzodiazepine binding sites. In comparison with the K+ channel opening effect which can be seen at concentrations as low as 0.1 mumol/l the contribution of this mechanism to the anticonvulsant activity of retigabine may be minor. Inhibitory effects observed on voltage activated Na+ and Ca++ channels as well as on kainate induced currents were only observed at the highest concentration tested (100 mumol/l) and can be considered non specific. No significant interaction with NMDA induced currents was observed.

PubMed Disclaimer

Similar articles

• Seeking a mechanism of action for the novel anticonvulsant lacosamide.
  Errington AC, Coyne L, Stöhr T, Selve N, Lees G. Errington AC, et al. Neuropharmacology. 2006 Jun;50(8):1016-29. doi: 10.1016/j.neuropharm.2006.02.002. Epub 2006 Apr 18. Neuropharmacology. 2006. PMID: 16620882
• The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
  Dost R, Rostock A, Rundfeldt C. Dost R, et al. Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr;369(4):382-90. doi: 10.1007/s00210-004-0881-1. Epub 2004 Mar 9. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15007538
• The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
  Gunthorpe MJ, Large CH, Sankar R. Gunthorpe MJ, et al. Epilepsia. 2012 Mar;53(3):412-24. doi: 10.1111/j.1528-1167.2011.03365.x. Epub 2012 Jan 5. Epilepsia. 2012. PMID: 22220513 Review.
• Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
  Splinter MY. Splinter MY. Clin Ther. 2012 Sep;34(9):1845-56.e1. doi: 10.1016/j.clinthera.2012.07.009. Epub 2012 Aug 21. Clin Ther. 2012. PMID: 22917854 Review.

Cited by

• Enhancing m currents: a way out for neuropathic pain?
  Rivera-Arconada I, Roza C, Lopez-Garcia JA. Rivera-Arconada I, et al. Front Mol Neurosci. 2009 Aug 4;2:10. doi: 10.3389/neuro.02.010.2009. eCollection 2009. Front Mol Neurosci. 2009. PMID: 19680469 Free PMC article.
• Mitochondrial Potassium Channels as Druggable Targets.
  Wrzosek A, Augustynek B, Żochowska M, Szewczyk A. Wrzosek A, et al. Biomolecules. 2020 Aug 18;10(8):1200. doi: 10.3390/biom10081200. Biomolecules. 2020. PMID: 32824877 Free PMC article. Review.
• M-channels (Kv7/KCNQ channels) that regulate synaptic integration, excitability, and spike pattern of CA1 pyramidal cells are located in the perisomatic region.
  Hu H, Vervaeke K, Storm JF. Hu H, et al. J Neurosci. 2007 Feb 21;27(8):1853-67. doi: 10.1523/JNEUROSCI.4463-06.2007. J Neurosci. 2007. PMID: 17314282 Free PMC article.
• Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo.
  Mora G, Tapia R. Mora G, et al. Neurochem Res. 2005 Dec;30(12):1557-65. doi: 10.1007/s11064-005-8834-8. Neurochem Res. 2005. PMID: 16362775
• Identifying the mechanism of action of the Kv7 channel opener, retigabine in the treatment of epilepsy.
  Zahra A, Liu R, Wang J, Wu J. Zahra A, et al. Neurol Sci. 2023 Nov;44(11):3819-3825. doi: 10.1007/s10072-023-06955-x. Epub 2023 Jul 13. Neurol Sci. 2023. PMID: 37442907 Review.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Georg Thieme Verlag Stuttgart, New York